News stories about AAC (NYSE:AAC) have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. AAC earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.6309615496684 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- AAC Holdings Inc (AAC) Receives Average Recommendation of “Buy” from Analysts (americanbankingnews.com)
- Baidu invests in Skyworth unit (europe.chinadaily.com.cn)
- AAC Holdings Inc (AAC) Director David C. Kloeppel Sells 5,000 Shares (americanbankingnews.com)
- AAC Holdings Inc (AAC) Chairman Michael T. Cartwright Sells 100,000 Shares (americanbankingnews.com)
Shares of AAC stock traded up $0.13 during midday trading on Wednesday, reaching $12.81. The company’s stock had a trading volume of 33,793 shares, compared to its average volume of 172,034. The company has a current ratio of 1.85, a quick ratio of 1.85 and a debt-to-equity ratio of 1.62. The company has a market cap of $294.90, a price-to-earnings ratio of 20.57 and a beta of 1.62. AAC has a 52-week low of $5.99 and a 52-week high of $13.06.
AAC has been the subject of a number of recent analyst reports. Zacks Investment Research raised AAC from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Tuesday, March 13th. Cantor Fitzgerald reissued a “buy” rating and issued a $14.00 price objective on shares of AAC in a report on Friday, January 5th. ValuEngine raised AAC from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. Finally, TheStreet lowered AAC from a “c-” rating to a “d+” rating in a report on Thursday, February 22nd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $11.33.
In other news, Director David C. Kloeppel sold 5,000 shares of the firm’s stock in a transaction on Thursday, March 15th. The stock was sold at an average price of $12.02, for a total transaction of $60,100.00. Following the completion of the sale, the director now directly owns 161,080 shares of the company’s stock, valued at approximately $1,936,181.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director David C. Kloeppel sold 10,000 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $9.50, for a total value of $95,000.00. Following the sale, the director now directly owns 202,580 shares of the company’s stock, valued at $1,924,510. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 130,000 shares of company stock valued at $1,519,100. 33.99% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect AAC (AAC) Share Price” was originally published by BBNS and is owned by of BBNS. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://baseballnewssource.com/2018/03/21/aac-aac-getting-somewhat-favorable-news-coverage-study-shows/2028751.html.
AAC Company Profile
AAC Holdings, Inc is a provider of inpatient and outpatient substance abuse treatment services for individuals with drug and alcohol addiction. The Company performs drug testing and diagnostics laboratory services and provides physician services to its clients. As of June 30, 2016, the Company operated 12 residential substance abuse treatment facilities located throughout the United States, focused on delivering clinical care and treatment solutions across 1,139 beds, which includes 636 licensed detoxification beds, and 18 standalone outpatient centers.
Receive News & Ratings for AAC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AAC and related companies with MarketBeat.com's FREE daily email newsletter.